SCHEMBL5537413

SCHEMBL5537413

Cc1cnc2ccc(O)cc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.57
CCR1 P32246 1/20 0.47
CCR5 P51681 1/20 0.47
CCR8 P51685 1/20 0.47
MAP4K4 O95819 1/20 0.46
CDK8 P49336 1/20 0.46
CLK2 P49760 1/20 0.46
CDK7 P50613 1/20 0.46
CDK9 P50750 1/20 0.46
CDK5 Q00535 1/20 0.46
ACVR1 Q04771 1/20 0.46
ROCK1 Q13464 1/20 0.46
DYRK1A Q13627 1/20 0.46
LRRK2 Q5S007 1/20 0.46
CLK4 Q9HAZ1 1/20 0.46
DYRK1B Q9Y463 1/20 0.46
KDM4E B2RXH2 1/20 0.46
PDE10A Q9Y233 6/20 0.44
ALDH1A1 P00352 2/20 0.42
MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methane SCHEMBL27619416 0.98 CYP1A2 (0.55) CYP1A2CCR1CCR5CCR8MAP4K4
Bicarbonate SCHEMBL28311931 0.90 CYP1A2 (0.47) CYP1A2CCR1CCR5CCR8MAP4K4
SCHEMBL5534632 0.84 ESR2 (0.59) CYP1A2CCR1CCR5CCR8KDM4E
SCHEMBL2000504 0.84 MAP4K4 (0.54) CYP1A2MAP4K4CDK8CLK2CDK7
SCHEMBL4572536 0.83 CYP1A2 (0.65) CYP1A2CCR1CCR5CCR8KDM4E
SCHEMBL20869436 0.77 MAP4K4 (0.44) MAP4K4CDK8CLK2CDK7CDK9
SCHEMBL16289378 0.76 MAP4K4 (0.46) MAP4K4CDK8CLK2CDK7CDK9
SCHEMBL22520176 0.76 CYP1A2 (0.57) CYP1A2CCR1CCR5CCR8KDM4E
SCHEMBL21632275 0.76 CYP1A2 (0.57) CYP1A2CCR1CCR5CCR8KDM4E
SCHEMBL12686649 0.76 CYP1A2 (0.57) CYP1A2CCR1CCR5CCR8KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0331899-B1 A method for the sequential oxidation of substituted-8-hydroxy-quinolines to produce substituted-pyridine-2,3-dicarboxylic acids AMERICAN CYANAMID CO (US) 1994-04-27 EP claimed
EP-0259687-B1 METHOD FOR THE PREPARATION OF PYRIDINE-2,3-DICARBOXYLIC ACIDS AMERICAN CYANAMID COMPANY (US) 1991-07-03 EP claimed
US-12528791-B2 Thyroid hormone receptor beta agonist compounds TERNS PHARMACEUTICALS, INC. (US) 2026-01-20 US disclosed
US-20250353855-A1 HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS INC (US) 2025-11-20 US disclosed
US-20220281849-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS TERNS PHARMACEUTICALS, INC. 2022-09-08 US disclosed
EP-4017875-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS Terns Pharmaceuticals, Inc. (US) 2022-06-29 EP disclosed
CN-114430743-A Thyroid hormone receptor beta agonist compounds 拓臻制药公司 2022-05-03 CN disclosed
WO-2021041237-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS Terns, Inc. (US) 2021-03-04 WO disclosed
WO-2021041237-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS Terns, Inc. (US) 2021-03-04 WO disclosed
CN-110343067-B Quaternary ammonium quinoline salt compound and preparation method and application thereof 中国石油化工股份有限公司 2020-12-04 CN disclosed
CN-110343067-A Quinoline quaternary ammonium compound and its preparation method and application 中国石油化工股份有限公司 2019-10-18 CN disclosed
EP-2813492-A1 AMIDE COMPOUND AND USE THEREOF FOR PEST CONTROL Sumitomo Chemical Co., Ltd (JP) 2014-12-17 EP disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
US-20130065922-A1 NOVEL AMIDES AS FUNGICIDES SYNGENTA CROP PROTECTION LLC (US) 2013-03-14 US disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed
EP-0247277-B1 PROCESS FOR THE PREPARATION OF 5-ALKYLQUINOLINIC ACIDS AND MEANS FOR CARRYING OUT THIS PROCESS RÜTGERSWERKE AKTIENGESELLSCHAFT (DE) 1991-09-11 EP disclosed
EP-0247277-A2 Process for the preparation of 5-alkylquinolinic acids and means for carrying out this process RÜTGERSWERKE AKTIENGESELLSCHAFT (DE) 1987-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 CYP1A2 659/4885CCR1 564/4885CCR5 551/4885
US-12528791-B2 Thyroid hormone receptor beta agonist compounds THRB, THRA, TSHR CYP1A2 1493/4885CCR1 382/4885CCR5 534/4885
US-20220281849-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS THRB, THRA, TSHR CYP1A2 2848/4885CCR1 2082/4885CCR5 1253/4885
US-20130065922-A1 NOVEL AMIDES AS FUNGICIDES CYP51A1, DDT, CYP4X1 CYP1A2 6/4885CCR1 2759/4885CCR5 4596/4885
US-20250353855-A1 HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HTT, HYPK, FH CYP1A2 1209/4885CCR1 4611/4885CCR5 4124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.